Mechanisms and pharmacology of diabetic neuropathy-experimental and clinical studies

Pharmacological Reports

Volumn 65, Issue 6, 2013, Pages 1601-1610

  Zychowska, Magdalena ^a   Rojewska, Ewelina ^a   Przewlocka, Barbara ^a   Mika, Joanna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Anticonvulsants; Antidepressants; Diabetic neuropathy; Neuroimmune interactions; Neuropathic pain; Opioids; Therapy

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDEHYDE REDUCTASE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; FRUCTOSE; GABAPENTIN; GLUCOSE; IDITOL DEHYDROGENASE; INOSITOL; LIDOCAINE; MEXILETINE; MILNACIPRAN; MORPHINE; NARCOTIC ANALGESIC AGENT; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; PAROXETINE; PREGABALIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEROTONIN UPTAKE INHIBITOR; SORBITOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALLODYNIA; ANALGESIA; BIOLOGICAL MODEL; CELL MEMBRANE PERMEABILITY; CLINICAL STUDY; DIABETIC NEUROPATHY; DIZZINESS; DRUG CONTRAINDICATION; ENZYME ACTIVITY; EXPERIMENTAL STUDY; GLIA CELL; GLYCATION; HUMAN; HYPERALGESIA; HYPERGLYCEMIA; NEUROPATHIC PAIN; NONHUMAN; OSMOTIC STRESS; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SEDATION; SWEATING; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DIABETES COMPLICATIONS; DIABETIC NEUROPATHIES; HUMANS; NEURALGIA;

EID: 84894152709     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71521-4     Document Type: Article

References (68)

1. Anjaneyulu M, Chopra K: Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice. Eur J Pharmacol, 2004, 497, 285-292. (Pubitemid 39164893)
2. Beyreuther B, Callizot N, Stöhr T: Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol, 2006, 539, 64-70. (Pubitemid 43783512)
3. Bishnoi M, Bosgraaf CA, Abooj M, Zhong L, Premkumar LS: Streptozotocin-induced early thermal hyperalgesia is independent of glycemic state of rats: Role of transient receptor potential vanilloid 1(TRPV1) and inflammatory mediators. Mol Pain, 2011, 7, 52.
4. Boyle J, Eriksson ME, Gribble L, Gouni R, Johnsen S, Coppini DV, Kerr D: Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care, 2012, 35, 2451-2458.
5. Brownlee M: Glycation products and the pathogenesis of diabetic complications; Diabetes Care, 1992, 15, 1835-1840.
6. Cegielska-Perun K, Bujalska-Zadrony M, Makulska-Nowak HE: Modification of morphine analgesia by venlafaxine in diabetic neuropathic pain model. Pharmacol Rep, 2012, 64, 1267-1275.
7. Christoph T, De Vry J, Tzschentke TM: Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neurosci Lett, 2010, 470, 91-94.
8. Clements RS Jr: Diabetic neuropathy-new concepts of its etiology. Diabetes, 1979, 28, 604-611. (Pubitemid 9202981)
9. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A: Study of the sensitivity of the diabetesinduced pain model in rats to a range of analgesics. Pain, 1994, 57, 153-160. (Pubitemid 24168732)
10. Czyyk A: Pathophysiology and diabetes clinic (Polish). PZWL, Warszawa 1987, 146-147.
11. Daulhac L, Mallet C, Courteix C, Etienne M, Duroux E, Privat AM, Eschalier A, Fialip J: Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol Pharmacol, 2006, 70, 1246-1254. (Pubitemid 44435976)
12. Devi P, Madhu K, Ganapathy B, Sarma G, John L, Kulkarni C: Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol, 2012, 44, 51-56.
13. Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT: Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain, 2007, 8, 315-324. (Pubitemid 46551873)
14. Drel VR, Lupachyk S, Shevalye H, Vareniuk I, Xu W, Zhang J, Delamere NA et al.: New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis fac-tor-a. Endocrinology, 2010, 151, 2547-2555.
15. Dyck PJ, Karnes JL, O'Brien P, Okazaki H, Lais A, Engelstad J: The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia. Ann Neurol, 1986, 19, 440-449. (Pubitemid 16116477)
16. Fisher SK, Heacock AM, Agranoff BW: Inositol lipids and signal transduction in the nervous system: An update. J Neurochem, 1992, 58, 18-38.
17. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med, 2005, 352, 1324-1334. (Pubitemid 40411499)
18. Gómez-Pérez FJ, Choza R, Ríos JM, Reza A, Huerta E, Aguilar CA, Rull JA: Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res, 1996, 27, 525-529. (Pubitemid 26411596)
19. Goodnick PJ, Breakstone K, Kumar A, Freund B, De-Vane CL: Nefazodone in diabetic neuropathy: Response and biology. Psychosom Med, 2000, 62, 599-600. (Pubitemid 30604805)
20. Hanna M, O'Brien C, Wilson MC: Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain, 2008, 12, 804-813.
21. Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ: An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Fam Pract, 2013, 14-28.
22. Ikeda T, Ishida Y, Naono R, Takeda R, Abe H, Nakamura T, Nishimori T: Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain. Neurosci Res, 2009, 63, 42-46.
23. Kimura J: Electrodiagnosis in diseases of nerve and muscle-principles and practice. Davis, Philadelphia, 1987, 464.
24. Kolosov A, Goodchild CS, Cooke I: CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: A comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med, 2010, 11, 262-273.
25. Kozma CM, Benson C, Slaton TL, Kim MS, Vorsanger GJ: Opioids before and after initiation of pregabalin in patients with diabetic peripheral neuropathy. Curr Med Res Opin, 2012, 28, 1485-1496.
26. Kuhad A, Bishnoi M, Chopra K: Anti-nociceptive effect of duloxetine in mouse model of diabetic neuropathic pain. Indian J Exp Biol, 2009, 47, 193-197.
27. Lang F: Mechanisms and significance of cell volume regulation. J Am Coll Nutr, 2007, 26, 613-623.
28. Lindner MD, Bourin C, Chen P, McElroy JF, Leet JE, Hogan JB, Stock DA, Machet F: Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy. Exp Clin Psychopharmacol, 2006, 14, 42-51.
29. Malik RA: The pathology of human diabetic neuropathy. Diabetes, 1997, 45, 50-53.
30. Martinez JA, Kasamatsu M, Rosales-Hernandez A, Hanson LR, Frey WH, Toth CC: Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states. Mol Pain, 2012, 8, article 3.
31. Matsunami T, Sato Y, Hasegawa Y, Ariga S, Kashimura H, Sato T, Yukawa M: Enhancement of reactive oxygen species and induction of apoptosis in streptozotocininduced diabetic rats under hyperbaric oxygen exposure. Int J Clin Exp Pathol, 2011, 4, 255-266.
32. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med, 1992, 326, 1250-1256.
33. Mert T, Gunes Y: Antinociceptive activities of lidocaine and the nav1.8 blocker a803467 in diabetic rats. J Am Assoc Lab Anim Sci, 2012, 51, 579-585.
34. Mika J, Osikowicz M, Rojewska E, Korostyñski M, Wawrzczak-Bargiea A, Przewocki R, Przewocka B: Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. Eur J Pharmacol, 2009, 623, 65-72.
35. Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J: Metabolic correction in the management of diabetic peripheral neuropathy: Improving clinical results beyond symptom control. Curr Clin Pharmacol, 2011, 6, 260-273.
36. Mixcoatl-Zecuatl T, Jolivalt CG: A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathy. Br J Pharmacol, 2011, 164, 159-169.
37. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT: Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain, 2007, 132, 289-300. (Pubitemid 350051566)
38. Oates PJ: Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol, 2002, 50, 325-392.
39. Ogawa K, Sasaki H, Kishi Y, Yamasaki H, Okamoto K, Yamamoto N, Hanabusa T et al.: A suspected case of proximal diabetic neuropathy predominantly presenting with scapulohumeral muscle weakness and deep aching pain. Diabetes Res Clin Pract, 2001, 54, 57-64. (Pubitemid 32781028)
40. Otto M, Bach FW, Jensen TS, Brøsen K, Sindrup SH: Escitalopram in painful polyneuropathy: A randomized, placebo-controlled, cross-over trial. Pain, 2008, 139, 275-283.
41. Pabreja K, Dua K, Sharma S, Padi SS, Kulkarni SK: Minocycline attenuates the development of diabetic neuropathic pain: Possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol, 2011, 661, 15-21.
42. Pavy-Le Traon A, Fontaine S, Tap G, Guidolin B, Senard JM, Hanaire H: Cardiovascular autonomic neuropathy and other complications in type 1 diabetes. Clin Auton Res, 2010, 20, 153-160.
43. Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain, 2004, 110, 697-706. (Pubitemid 39036802)
44. Said G: Diabetic neuropathy-a review. Nat Clin Pract Neurol, 2007, 3, 331-340.
45. Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C: Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin, 2011, 27, 151-162.
46. Simpson DA: Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis, 2001, 3, 53-62. (Pubitemid 33130299)
47. Sindrup SH, Gram LF, Skjold T, Frøland A, Beck-Nielsen H: Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther, 1990, 47, 509-515. (Pubitemid 20151477)
48. Sindrup SH, Otto M, Finnerup NB, Jensen TS: Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol, 2005, 96, 399-409. (Pubitemid 40835693)
49. Smith H: Analgesic actions of insulin. J Neuropathic Pain Symptom Palliat, 2006, 1, 23-28. (Pubitemid 44846672)
50. Sounvoravong S, Nakashima MN, Wada M, Nakashima K: Modification of antiallodynic and antinociceptive effects of morphine by peripheral and central action of fluoxetine in a neuropathic mice model. Acta Biol Hung, 2007, 58, 369-379. (Pubitemid 351160511)
51. Sundkvist G, Dahlin LB, Nilsson H, Eriksson KF, Lindgärde F, Rosén I, Lattimer SA et al.: Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance. Diabet Med, 2000, 17, 259-268. (Pubitemid 30266119)
52. Tatoñ J.: Practical diabetology (Polish). PZWL, Warszawa 1993, 13-16, 32-34, 171, 277-305.
53. Tembhurne SV, Sakarkar DM: Effect of fluoxetine on an experimental model of diabetes-induced neuropathic pain perception in the rat. Indian J Pharm Sci, 2011, 73, 621-625.
54. Thornalley PJ: Glycation in diabetic neuropathy: Characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol, 2002, 50, 37-57.
55. Tsuda M, Ueno H, Kataoka A, Tozaki-Saitoh H, Inoue K: Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling. Glia, 2008, 56, 378-386. (Pubitemid 351212947)
56. Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB: Diabetic neuropathies. Diabetes Care, 1992, 15, 1926-1975.
57. Vlassara H, Brownlee M, Cerami A: Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. Diabetes, 1983, 32, 670-674. (Pubitemid 13062852)
58. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF: Norman Cousins Lecture. Glia as the "bad guys": Implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun, 2007, 21, 131-146. (Pubitemid 46038918)
59. Wattiez AS, Libert F, Privat AM, Loiodice S, Fialip J, Eschalier A, Courteix C: Evidence for a differential opioidergic involvement in the analgesic effect of antidepressants: Prediction for efficacy in animal models of neuropathic pain? Br J Pharmacol, 2011, 163, 792-803.
60. Wattiez AS, Barrière D, Dupuis A, Courteix C: Rodent models of painful diabetic neuropathy: What can we learn from them? J Diabetes Metab, 2012, http://dx.doi.org/10.4172/2155-6156.S5-008
61. Williams J, Haller VL, Stevens DL,Welch SP: Decreased basal endogenous opioid levels in diabetic rodents: Effects on morphine and delta-9- tetrahydrocannabinoidinduced antinociception. Eur J Pharmacol, 2008, 584, 78-86.
62. Williams SK, Howarth NL, Devenny JJ, Bitensky MW: Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. Proc Natl Acad Sci USA, 1982, 79, 6546-6550. (Pubitemid 13207531)
63. Wilson RC: The use of low-dose trazodone in the treatment of painful diabetic neuropathy. J Am Podiatr Med Assoc, 1999, 89, 468-471.
64. Wodarski R, Clark AK, Grist J, Marchand F, Malcangio M: Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats. Eur J Pain, 2009, 13, 807-811.
65. www.diabetes.niddk.nih.gov/dm/pubs/neuropathies/Neuropathies-508.pdf
66. Yamamoto H, Shimoshige Y, Yamaji T, Murai N, Aoki T, Matsuoka N: Pharmacological characterization of standard analgesics on mechanical allodynia in streptozotocin-induced diabetic rats. Neuropharmacology, 2009, 57, 403-408.
67. Zin CS, Nissen LM, O'Callaghan JP, Duffull SB, Smith MT, Moore BJ: A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain, 2010, 11, 462-471.
68. Zychowska M, Rojewska E, Kreiner G, Nalepa I, Przewlocka B, Mika J: Minocycline influences the antiinflammatory interleukins and enhances the effectiveness of morphine under mice diabetic neuropathy. J Neuroimmunol, 2013, 262, 35-45.